Rocket Companies Inc Q4 Earnings Summary

Below are the earnings highlights for Rocket Companies Inc (RKT):

Earnings: -$493 million in Q4 vs. $865 million in the same period last year.
EPS: -$0.14 in Q4 vs. $0.32 in the same period last year.
Excluding items, Rocket Companies Inc reported adjusted earnings of -$197 million or -$0.10 per share for the period.

Analysts projected -$0.11 per share
Revenue: $481 million in Q4 vs. $2.59 billion in the same period last year.

-Guidance:
Next quarter revenue guidance: $700-$850 mln

Verisk Analytics Inc. Q4 Profit Falls

Verisk Analytics Inc. (VRSK) released earnings for fourth quarter that decreased from last year

The company’s bottom line totaled $61.2 million, or $0.39 per share. This compares with $141.8 million, or $0.87 per share, in last year’s fourth quarter.

Excluding items, Verisk Analytics Inc. reported adjusted earnings of $224.8 million or $1.43 per share for the period.

The company’s revenue for the quarter rose 0.0% to $630.4 million from $630.3 million last year.

Verisk Analytics Inc. earnings at a glance (GAAP) :

-Earnings (Q4): $61.2 Mln. vs. $141.8 Mln. last year.
-EPS (Q4): $0.39 vs. $0.87 last year.
-Revenue (Q4): $630.4 Mln vs. $630.3 Mln last year.

GoodRx Holdings, Inc. Q4 Earnings Summary

Below are the earnings highlights for GoodRx Holdings, Inc. (GDRX):

Earnings: -$1.97 million in Q4 vs. -$39.91 million in the same period last year.
EPS: $0.00 in Q4 vs. -$0.10 in the same period last year.
Analysts projected $0.05 per share
Revenue: $184.1 million in Q4 vs. $213.3 million in the same period last year.

-Guidance:
Next quarter revenue guidance: $181-183 mln

First Solar, Inc. Q4 Earnings Summary

Below are the earnings highlights for First Solar, Inc. (FSLR):

Earnings: -$7.5 million in Q4 vs. $131.4 million in the same period last year.
EPS: -$0.07 in Q4 vs. $1.23 in the same period last year.
Analysts projected -$0.15 per share
Revenue: $1.00 billion in Q4 vs. $907.3 million in the same period last year.

Nektar Therapeutics Q4 Loss decreases, beats estimates

Nektar Therapeutics (NKTR) announced Loss for fourth quarter that decreased from last year and beat the Street estimates.

The company’s bottom line totaled -$59.69 million, or -$0.32 per share. This compares with -$145.65 million, or -$0.79 per share, in last year’s fourth quarter.

Analysts on average had expected the company to earn -$0.45 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter fell 12.0% to $22.02 million from $25.01 million last year.

Nektar Therapeutics earnings at a glance (GAAP) :

-Earnings (Q4): -$59.69 Mln. vs. -$145.65 Mln. last year.
-EPS (Q4): -$0.32 vs. -$0.79 last year.
-Analyst Estimates: -$0.45
-Revenue (Q4): $22.02 Mln vs. $25.01 Mln last year.

FDA Approves Regeneron's Kevzara To Treat Inflammatory Rheumatic Disease

The U.S. Food and Drug Administration approved Kevzara (sarilumab) for the treatment of polymyalgia rheumatica, an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper, Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said in a statement on Tuesday.

Kevzara is now approved to treat two chronic inflammatory disorders.

Kevzara was previously approved for the treatment of moderately-to-severely active rheumatoid arthritis (RA) in adult patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs.

Polymyalgia rheumatica can be an incapacitating disease, causing painful disease flares in multiple parts of the body that leave people fatigued and unable to fully perform everyday activities. Polymyalgia rheumatica generally affects people who are 50 years and older.

Corticosteroids have been the primary treatment to date, but many patients do not adequately respond to steroids or cannot be tapered off steroids, which puts such patients at risk of complications from long-term steroid therapy.

For More Such Health News, visit rttnews.com

Beiersdorf FY Profit Increases – Quick Facts

German consumer major Beiersdorf AG (BDRFY.PK,BDRFF.PK) reported that its profit after tax for fiscal year 2022 increased to 771 million euros from the prior year’s 655 million euros, with earnings per share improving to 3.33 euros from 2.81 euros last year.

Operating results (EBIT), excluding special factors, improved to 1.2 billion euros from 993 million euros in the prior year.

Group sales for the year rose to 8.8?billion euros from 7.6 billion euros in the prior year, while it was up 10.2% in organic terms.

For the full year 2023, Beiersdorf expects organic sales growth for the Consumer Business Segment to be in the mid-single-digit range. The EBIT margin excluding special factors is expected to be 50bps above the previous year’s level, which is in line with the mid-term goal for profitable growth in the Consumer Segment.

For the tesa Business Segment, Beiersdorf expects sales growth to be in the mid-single-digit range. The EBIT margin is expected to be slightly below the previous year’s level.

Organic group sales growth for fiscal year 2023 is expected to be in the mid-single-digit range and the consolidated EBIT margin excluding special factors will be slightly above the previous year’s level.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Kuehne + Nagel FY22 Earnings Rise, Lifts Dividend; Sees Growth In FY23

Kuehne + Nagel International (KHNGY), a Swiss transport and logistics company, on Wednesday reported a rise in earnings for 2022, amidst an increase in revenue, driven by firm performance of all business units.

Meanwhile, due to the overall economic slowdown, the fourth- quarter net earnings fell 39 percent from last year and revenues declined 20 percent.

For 12-month period, Schindellegi-headquartered firm posted a net earnings of CHF 2.810 billion, higher than CHF 2.155 billion of 2021.

Basic earnings per share were CHF 22.15, compared with CHF 16.92 a year ago.

EBIT moved up to CHF 3.763 billion from previous year’s CHF 2.946 billion.

EBITDA was at CHF 4.532 billion as against CHF 3.679 billion a year ago.

Net turnover rose to CHF 39.398 billion from previous year’s CHF 32.801 billion.

An annual dividend of CHF 14 per share will be paid, which corresponds to an increase of 40 percent compared with the previous year.

Looking ahead, Kuehne + Nagel, said, “From today’s perspective, the macroeconomic environment will remain challenging in 2023 due to geopolitical developments and inflation. However, we expect the positive growth and earnings trend that has continued for many years to continue this year, albeit excluding the exceptional business volumes and results in financial years 2021 and 2022, which were the result of a corona-related special economic situation.”